Inmune Bio, Inc. (INMB): Entry into a Material Definitive Agreement
Inmune Bio, Inc. (INMB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 ea029662401ex10-1.htm FORM OF INDUCEMENT LETTER Exhibit 10.1 INMUE BIO INC. 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 June 29, 2026 To the Holder of April 2024 Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase
How this was made
The 30-second read
Why it matters
The disclosed terms can affect INMB’s expected cash receipts (from exercised warrants) and the timing of potential share issuance (via maturity extension and beneficial ownership limitations).
Market read
This is a capital-structure event (warrant repricing/extension) disclosed via SEC 8-K, relevant for dilution and cash-flow expectations.
What to watch
Traders may need to model beneficial-ownership limitation mechanics (9.99%/Section 2(d)(viii)) that can delay issuance and affect perceived dilution risk.
Background
The 8-K Item 1.01 attaches an inducement letter for holders of April 2024 common stock purchase warrants, offering to exercise 50% at a reduced price and amend the remaining 50% to extend maturity.
Ticker impact
Inmune Bio entered a material definitive agreement offering warrant holders a reduced $1.40 exercise price and extending remaining warrant maturity to Dec. 31, 2027.
Likely modest, with direction dependent on how much of the remaining warrants are expected to be exercised during the June 30, 2026 exercise window.
The filing is a primary SEC disclosure of warrant terms (reduced exercise price + maturity extension). It is material to capital structure, but the text provides no size of participation or expected proceeds, limiting conviction on magnitude/direction.
Market effects
Adds another example of biotech using warrant inducements to manage overhang and extend maturities rather than immediate repricing.
None indicated.
None indicated.
Counterpoint
If participation is low, the reduced exercise price may not translate into meaningful cash proceeds, making the extension more about deferring dilution than improving fundamentals.
Key entities
- issuerInmune Bio, Inc.
Company offering warrant inducement: reduced exercise price to $1.40 and extension of remaining warrant maturity to Dec. 31, 2027.
- executiveCory Ellspermann
Chief Financial Officer signing the inducement letter.
